Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Enliven Therapeutics, Inc.

NASDAQ: ELVN · Life Sciences · 8 alerts · CIK 1672619

Share price
$47.62Close, Nov 16
Market cap
$3.5B
Shares outstanding
73.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Enliven Therapeutics, Inc. filings on SEC EDGAR ↗

4:18 PM ET 10-Q
Financial Results

Enliven Therapeutics Q3 2026 Results: Net Loss of $27.7M, Loss Widens

Enliven Therapeutics reported a significant increase in liquidity, with cash, cash equivalents, and marketable securities totaling approximately $884.4 million as of September 30, 2026, compared to $462.6 million at year-end 2025. The company is advancing its clinical pipeline, specifically relcobatinib (ELVN-001), and preparing for the ENABLE-2 Phase 3 pivotal trial.

Key figure
Net loss $27.7M
4:15 PM ET 8-K
Financial Results

Enliven Therapeutics Financial Results

Enliven Therapeutics reported third quarter 2026 financial results and announced alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib. The company ended the quarter with $884.4 million in cash and marketable securities, providing a projected cash runway into 2030.

“This quarter marked an important milestone for Enliven as we reached alignment with the FDA on the final design of ENABLE-2, providing a clear path to initiate our first pivotal trial.”

Rick Fair, Chief Executive Officer of Enliven

“As we approach year-end, we remain confident in relcobatinib's potential to become a best-in-class therapy for patients with CML and are focused on executing our Phase 3 development program.”

Rick Fair, Chief Executive Officer of Enliven
5:54 PM ET Form 4
Insider Selling

Enliven Therapeutics CFO Benjamin Hohl Sells $232K of Stock

Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $38.48 a share, worth $232K in total on Oct 19, 2026. Shares held after the trade: 38,000 (-13.7%).

Value
$232K
Shares
6,018
Price
$38.48
Role
CFO
Holding change
-13.7%
Trade date
Oct 19, 2026
5:52 PM ET Form 4
Insider Selling

Enliven Therapeutics CMO Helen Louise Collins Sells $192K of Stock

Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $38.47 a share, worth $192K in total on Oct 19, 2026. Shares held after the trade: 25,000 (-16.7%).

Value
$192K
Shares
5,000
Price
$38.47
Role
CMO
Holding change
-16.7%
Trade date
Oct 19, 2026
4:40 PM ET 8-K
Leadership Change

Enliven Therapeutics Leadership Change

Enliven Therapeutics appointed Kristine Ball to its Board of Directors and Audit Committee, effective October 14, 2026. Ms. Ball, an experienced biopharmaceutical executive, joins as the company prepares to initiate a pivotal Phase 3 trial for relcobatinib. Her compensation includes $55,000 in annual cash fees and stock options valued at approximately $650,000.

Counterparty
Kristine Ball
4:57 PM ET Form 4
Insider Selling

Enliven Therapeutics Director J. Scott Garland Sells $607K of Stock

J. Scott Garland, Director, sold 13,000 shares of Enliven Therapeutics, Inc. at $46.67 a share, worth $607K in total on Oct 1, 2026. Shares held after the trade: 0 (-100.0%).

Value
$607K
Shares
13,000
Price
$46.67
Role
Director
Holding change
-100.0%
Trade date
Oct 1, 2026
5:24 PM ET Form 4
Insider Selling

Enliven Therapeutics CFO Benjamin Hohl Sells $303K of Stock

Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $50.03 to $51.49 a share (average $50.35) in 3 transactions, worth $303K in total on Sep 17, 2026. Shares held after the trade: 38,000 (-0.8%).

Value
$303K
Shares
6,018
Average price
$50.35
Role
CFO
Holding change
-0.8%
Trade date
Sep 17, 2026
5:22 PM ET Form 4
Insider Selling

Enliven Therapeutics CMO Helen Louise Collins Sells $252K of Stock

Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $50.03 to $51.48 a share (average $50.35) in 3 transactions, worth $252K in total on Sep 17, 2026. Shares held after the trade: 25,000 (-1.0%).

Value
$252K
Shares
5,000
Average price
$50.35
Role
CMO
Holding change
-1.0%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.